US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
US6639061B1
(en)
|
1999-07-07 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
C3′-methylene hydrogen phosphonate oligomers and related compounds
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
AU4155696A
(en)
|
1994-11-09 |
1996-06-06 |
Regents Of The University Of California, The |
Immunoliposomes that optimize internalization into target cells
|
CA2589421C
(en)
|
1996-03-27 |
2012-12-18 |
Genentech, Inc. |
Erbb3 antibodies
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
CA2246429C
(en)
|
1996-03-27 |
2007-07-24 |
Genentech, Inc. |
Erbb3 antibodies
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
NZ333325A
(en)
|
1996-07-12 |
2000-06-23 |
Genentech Inc |
Recombinant chimeric heteromultimer adhesins comprising extracellular domains of ErbB receptors
|
US20020002276A1
(en)
|
1997-02-10 |
2002-01-03 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
US6723694B1
(en)
|
1997-05-21 |
2004-04-20 |
The Children's Medical Center Corp. |
Short peptides which selectively modulate intracellular signalling
|
US6416168B1
(en)
|
1997-07-15 |
2002-07-09 |
Silverbrook Research Pty Ltd |
Pump action refill ink jet printing mechanism
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
US20010023241A1
(en)
|
1998-02-04 |
2001-09-20 |
Sliwkowski Mark X. |
Use of heregulin as a growth factor
|
AU2581599A
(en)
|
1998-02-04 |
1999-08-23 |
Genentech Inc. |
Use of heregulin as an epithelial cell growth factor
|
AU2003203831B2
(en)
|
1998-02-04 |
2006-08-10 |
Genentech, Inc. |
Use of heregulin as an epithelial cell growth factor
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
DK1064382T3
(da)
|
1998-03-17 |
2008-12-08 |
Genentech Inc |
Homologe polypeptider til VEGF og BMP1
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
AU2004200705A1
(en)
|
1998-05-15 |
2004-03-18 |
Imclone Systems Incorporated |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
|
JP2002515511A
(ja)
|
1998-05-15 |
2002-05-28 |
イムクローン システムズ インコーポレイティド |
放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
|
ZA200007412B
(en)
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
CA2345899A1
(en)
|
1998-11-07 |
2000-05-18 |
Genentech, Inc. |
Method for enhancing proliferation of inner ear hair cells using ligands for her2 and/or her3 receptors
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
JP2002544123A
(ja)
*
|
1999-04-14 |
2002-12-24 |
スミスクライン・ビーチャム・コーポレイション |
エリトロポイエチン受容体抗体
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
US6710186B2
(en)
|
1999-06-14 |
2004-03-23 |
Wisconsin Alumni Research Foundation |
Oligomers and polymers of di-substituted cyclic imino carboxylic acids
|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
NZ515975A
(en)
|
1999-06-25 |
2004-01-30 |
Genentech Inc |
Anti-ErbB antibody-maytansinoid conjugates useful in the treatment of tumors characterised by the overexpression of an ErbB receptor
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
KR100850389B1
(ko)
|
1999-06-25 |
2008-08-04 |
제넨테크, 인크. |
인간화 항-ErbB2 항체 및 항-ErbB2 항체를 사용한치료 방법
|
PL202369B1
(pl)
|
1999-08-27 |
2009-06-30 |
Genentech Inc |
Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
|
US7732157B1
(en)
|
1999-09-30 |
2010-06-08 |
Tumor Biology Investment Group |
Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods
|
US7390632B2
(en)
|
1999-09-30 |
2008-06-24 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
US7651703B2
(en)
|
1999-10-15 |
2010-01-26 |
Genentech, Inc. |
Injection vehicle for polymer-based formulations
|
JP2003519796A
(ja)
|
2000-01-12 |
2003-06-24 |
ヴェンタナ メディカル システムズ インコーポレイテッド |
画像分析によるタンパク質の定量法
|
ES2267593T3
(es)
|
2000-02-16 |
2007-03-16 |
Genentech, Inc. |
Anticuerpos anti-april y celulas hibridomas.
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
AU2007216733A1
(en)
|
2000-04-11 |
2007-09-27 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
AUPQ903400A0
(en)
|
2000-07-27 |
2000-08-17 |
Oh, Young June |
Navigable search engine
|
US6277640B1
(en)
|
2000-07-31 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Her-3 expression
|
DE50112200D1
(de)
|
2000-11-24 |
2007-04-26 |
Freudenberg Carl Kg |
Bodenwischer
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
AU2008200400B2
(en)
|
2001-01-17 |
2012-06-07 |
Aptevo Research And Development Llc |
Binding domain-immunoglobulin fusion proteins
|
EP1228766A1
(en)
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
CN1312181C
(zh)
|
2001-02-12 |
2007-04-25 |
米德列斯公司 |
抗Fcα受体(CD89)的人单克隆抗体
|
US7638598B2
(en)
|
2001-04-06 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
ErbB interface peptidomimetics and methods of use thereof
|
WO2002087618A1
(fr)
|
2001-04-27 |
2002-11-07 |
Takeda Chemical Industries, Ltd. |
Methode de prevention et de traitement du cancer
|
KR20040082273A
(ko)
|
2001-05-21 |
2004-09-24 |
아클라라 바이오사이언시스 인코퍼레이티드 |
단백질 분석을 위한 방법 및 조성물
|
US7745398B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
AU2002314495A1
(en)
|
2001-06-20 |
2003-01-02 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
US7276658B2
(en)
|
2001-06-21 |
2007-10-02 |
Akzo Nobel N.V. |
Manufacturing a solar cell foil connected in series via a temporary substrate
|
WO2003011897A1
(en)
|
2001-07-27 |
2003-02-13 |
The Regents Of The University Of California |
Modulation of heregulin and her3 interaction
|
DE10137374A1
(de)
|
2001-07-31 |
2003-02-27 |
Ipk Inst Fuer Pflanzengenetik |
Verfahren zur Herstellung von Arachidonsäure in transgenen Organismen
|
WO2003012072A2
(en)
|
2001-08-03 |
2003-02-13 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies to activated erbb family members and methods of use thereof
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
AU2008200654B2
(en)
|
2001-08-09 |
2010-04-29 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Inhibitors of HER3 activity
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
JP4132912B2
(ja)
|
2002-03-26 |
2008-08-13 |
日東電工株式会社 |
ゲル電解質とその製造方法とその利用
|
EP1495123B1
(en)
|
2002-03-26 |
2013-10-30 |
Zensun (Shanghai) Science and Technology Limited |
Erbb3 based methods and compositions for treating neoplasms
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
US7323553B2
(en)
|
2002-04-26 |
2008-01-29 |
Genentech, Inc. |
Non-affinity purification of proteins
|
US20040229380A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB heterodimers as biomarkers
|
US20040229293A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
Surface receptor complexes as biomarkers
|
US20040229299A1
(en)
|
2002-05-21 |
2004-11-18 |
Badal M. Youssouf |
Intracellular complexes as biomarkers
|
US20040229294A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB surface receptor complexes as biomarkers
|
WO2004000102A2
(en)
|
2002-06-19 |
2003-12-31 |
Abgenix, Inc. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
JP5069843B2
(ja)
|
2002-07-15 |
2012-11-07 |
ジェネンテック, インコーポレイテッド |
抗ErbB2抗体を用いる処置に応答性である腫瘍を同定するための方法
|
ATE442589T1
(de)
|
2002-07-25 |
2009-09-15 |
Aclara Biosciences Inc |
Nachweis der rezeptoroligomerisierung
|
GB0225282D0
(en)
|
2002-10-31 |
2002-12-11 |
Astrazeneca Ab |
assay
|
WO2004065417A2
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
CN1798770B
(zh)
|
2003-04-04 |
2010-06-09 |
洛桑大学 |
用于治疗癌症的多聚肽体
|
WO2004094463A2
(en)
|
2003-04-18 |
2004-11-04 |
University Of Florida Research Foundation, Inc. |
Peptide inhibitors of autophosphorylation protein kinases
|
MXPA05012939A
(es)
|
2003-05-30 |
2006-05-17 |
Astrazeneca Uk Ltd |
Procedimiento.
|
JP2007526447A
(ja)
|
2003-06-06 |
2007-09-13 |
ジェネンテック・インコーポレーテッド |
HGFβ鎖とC−MET間の相互作用の調節
|
US20040254108A1
(en)
|
2003-06-13 |
2004-12-16 |
Jing Ma |
Preparation and application of anti-tumor bifunctional fusion proteins
|
US20050232931A1
(en)
|
2003-06-13 |
2005-10-20 |
Oncomax Acquisition Corp. |
Preparation and application of anti-tumor bifunctional fusion proteins
|
WO2005001048A2
(en)
|
2003-06-13 |
2005-01-06 |
Oncomax Acquisition Corp. |
Preparation and application of anti-tumor bifunctional fusion proteins
|
US6836094B1
(en)
|
2003-07-01 |
2004-12-28 |
International Truck Intellectual Property Company, Llc |
Motor vehicle battery disconnect switch circuits
|
US7531649B2
(en)
|
2003-07-18 |
2009-05-12 |
The Regents Of The University Of California |
Aptamers to human epidermal growth factor receptor-3
|
DK1648940T3
(en)
|
2003-07-28 |
2016-08-15 |
Genentech Inc |
Reduction of leaching of protein A during protein A affinity chromatography
|
CA2534362A1
(en)
|
2003-08-05 |
2005-02-17 |
Euro-Celtique S.A. |
Erbb receptor methods and kits for monitoring chemotherapy resistance
|
JP4818917B2
(ja)
|
2003-08-08 |
2011-11-16 |
イミューノメディクス、インコーポレイテッド |
腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体
|
JP2007502417A
(ja)
|
2003-08-11 |
2007-02-08 |
モノグラム バイオサイエンシズ,インコーポレーテッド |
分子複合体の検出および特徴づけ
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
WO2005037071A2
(en)
|
2003-10-14 |
2005-04-28 |
Monogram Biosciences, Inc. |
Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
|
EP1680666A4
(en)
|
2003-10-27 |
2008-03-26 |
Monogram Biosciences Inc |
ANTI-THERAPEUTIC HUMAN ANTIBODY DETECTION
|
BRPI0416190A
(pt)
|
2003-11-06 |
2007-01-23 |
Pfizer Prod Inc |
combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro
|
US7754441B2
(en)
|
2003-11-17 |
2010-07-13 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
JP4658967B2
(ja)
|
2003-12-24 |
2011-03-23 |
ジェネンテック, インコーポレイテッド |
造血系起源の腫瘍の治療のための組成物と方法
|
WO2006107617A2
(en)
|
2005-04-06 |
2006-10-12 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
WO2005079434A2
(en)
|
2004-02-17 |
2005-09-01 |
The University Of North Carolina At Chapel Hill |
Modulation of epidermal growth factor heterodimer activity
|
CA2556832A1
(en)
|
2004-02-20 |
2005-09-09 |
The Trustees Of The University Of Pennsylvania |
Binding peptidomimetics and uses of the same
|
CA2564538A1
(en)
|
2004-04-22 |
2005-12-01 |
Oregon Health And Science University |
Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors
|
RU2433831C2
(ru)
|
2004-05-05 |
2011-11-20 |
Мерримак Фармасьютикалз, Инк. |
Биспецифические связывающие агенты для модулирования биологической активности
|
KR20120133403A
(ko)
|
2004-06-01 |
2012-12-10 |
도만티스 리미티드 |
증강된 혈청 반감기를 가지는 이특이성 융합 항체
|
BRPI0510883B8
(pt)
|
2004-06-01 |
2021-05-25 |
Genentech Inc |
composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
|
GT200500155A
(es)
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
JP2008504239A
(ja)
|
2004-06-24 |
2008-02-14 |
ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ |
複合体およびその治療的使用
|
MX2007000723A
(es)
|
2004-07-22 |
2007-03-12 |
Genentch Inc |
Composicion de anticuerpos her2.
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
PL1791565T3
(pl)
|
2004-09-23 |
2016-10-31 |
|
Modyfikowane cysteiną przeciwciała i koniugaty
|
CA2583230A1
(en)
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
EP1817340B1
(en)
|
2004-11-12 |
2012-05-16 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
MX2007006103A
(es)
|
2004-11-22 |
2007-07-20 |
Vertex Pharma |
Pirrolopirazinas y pirazolopirazinas de utilidad como inhibidores de proteinquinasas.
|
US7947839B2
(en)
|
2004-12-01 |
2011-05-24 |
Genentech, Inc. |
Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
|
CA2589885A1
(en)
*
|
2004-12-03 |
2006-06-08 |
Schering Corporation |
Biomarkers for pre-selection of patients for anti-igf1r therapy
|
MX2007006529A
(es)
|
2004-12-07 |
2007-06-22 |
Genentech Inc |
Seleccionar pacientes para terapia con un inhibidor her.
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
WO2006068640A1
(en)
|
2004-12-21 |
2006-06-29 |
Cell Signaling Technology, Inc. |
Protein phosphorylation in egfr-signaling pathways
|
SI1699826T1
(sl)
|
2005-01-05 |
2009-08-31 |
Ngsges M B H F Star Biotechnol |
Sintetske imunoglobulinske domene z vezavnimi lastnostmi, konstruiranimi v regijah molekule, različnih od regij, ki določajo komplementarnost
|
JP2008527978A
(ja)
|
2005-01-11 |
2008-07-31 |
モレキュラー ロジックス,インコーポレイテッド |
Pan−HERアンタゴニストおよび使用方法
|
TWI441646B
(zh)
|
2005-01-21 |
2014-06-21 |
Genentech Inc |
帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
|
WO2006084018A2
(en)
|
2005-02-02 |
2006-08-10 |
Monogram Biosciences, Inc. |
Methods for determining responsiveness to cancer therapy
|
EP1871805B1
(en)
|
2005-02-07 |
2019-09-25 |
Roche Glycart AG |
Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
|
US7718626B2
(en)
|
2005-02-17 |
2010-05-18 |
University Of Maryland, Baltimore |
ErbB3 binding protein compositions and methods of use
|
CN101163503B
(zh)
|
2005-02-23 |
2013-05-08 |
健泰科生物技术公司 |
使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
|
JP2008531557A
(ja)
|
2005-02-23 |
2008-08-14 |
メリマック ファーマシューティカルズ インコーポレーティッド |
生物活性を調節するための二重特異性結合剤
|
US7210618B2
(en)
|
2005-03-03 |
2007-05-01 |
Nokia Corporation |
Mobile communication terminal
|
EP1856158A4
(en)
|
2005-03-07 |
2010-07-28 |
Targeted Molecular Diagnostics |
TYROSINE KINASE INHIBITOR COMPOSITIONS AND METHODS OF MAKING SAME AND USE THEREOF IN TREATING DISEASE
|
TW200642695A
(en)
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
JP5129122B2
(ja)
|
2005-04-26 |
2013-01-23 |
トリオン ファーマ ゲーエムベーハー |
癌治療のための抗体およびグルココルチコイドの組み合わせ
|
US20090298061A1
(en)
|
2005-07-29 |
2009-12-03 |
Siemens Healthcare Diagnostics Inc. |
Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy
|
SG192479A1
(en)
|
2005-08-26 |
2013-08-30 |
Roche Glycart Ag |
Modified antigen binding molecules with altered cell signaling activity
|
US20070172844A1
(en)
|
2005-09-28 |
2007-07-26 |
University Of South Florida |
Individualized cancer treatments
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
US20090252681A1
(en)
|
2005-10-11 |
2009-10-08 |
Ablynx N.V. |
Nanobodies and Polypeptides Against EGFR and IGF-IR
|
WO2007050495A2
(en)
|
2005-10-26 |
2007-05-03 |
Children's Medical Center Corporation |
Method to prognose response to anti-egfr therapeutics
|
EP1792622A1
(en)
|
2005-11-11 |
2007-06-06 |
GPC Biotech AG |
Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
|
SI2481753T1
(en)
|
2005-12-13 |
2018-06-29 |
Eli Lilly And Company |
Anti-IL-17 antibodies
|
EP1800695A1
(en)
|
2005-12-21 |
2007-06-27 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Immuno-RNA-constructs
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
MX2008009970A
(es)
|
2006-02-01 |
2008-11-19 |
Univ Johns Hopkins |
Conjugados de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciosos.
|
JP5374359B2
(ja)
|
2006-03-17 |
2013-12-25 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
安定化されたポリペプチド化合物
|
JP2009532393A
(ja)
|
2006-04-07 |
2009-09-10 |
コペンハーゲン ユニバーシティ |
ErbB受容体由来ペプチド断片
|
BRPI0712077A2
(pt)
|
2006-05-01 |
2012-01-17 |
Genentech Inc |
prolongamento de sobrevivência de pacientes com cáncer com niveis elevados de egf ou tgf-alfa
|
CN101627053A
(zh)
*
|
2006-06-12 |
2010-01-13 |
西福根有限公司 |
泛细胞表面受体特异的治疗剂
|
MX2008015524A
(es)
|
2006-06-12 |
2009-01-13 |
Trubion Pharmaceuticals Inc |
Proteinas de union multivalentes monocatenarias con funcion efectora.
|
WO2007145832A2
(en)
|
2006-06-13 |
2007-12-21 |
Shulman Zachary J |
Infant harness support
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
US20100316626A1
(en)
|
2006-08-11 |
2010-12-16 |
The Government Of The United States Of America As Represented By The Secretary |
Methods for treatment and diagnosis of psychiatric disorders
|
DK2059533T3
(da)
|
2006-08-30 |
2013-02-25 |
Genentech Inc |
Multispecifikke antistoffer
|
US8936780B2
(en)
|
2006-08-30 |
2015-01-20 |
Advanced Cardiovascular Systems, Inc. |
Stimuli responsive polyester amide particles
|
CN101484469B
(zh)
|
2006-08-31 |
2012-12-12 |
弗·哈夫曼-拉罗切有限公司 |
生产胰岛素样生长因子-ⅰ的方法
|
US20080076139A1
(en)
|
2006-09-21 |
2008-03-27 |
Sharat Singh |
Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
|
WO2011008990A1
(en)
|
2009-07-15 |
2011-01-20 |
Prometheus Laboratories Inc. |
Drug selection for gastric cancer therapy using antibody-based arrays
|
ES2398596T3
(es)
|
2006-09-21 |
2013-03-20 |
Nestec S.A. |
Matrices a base de anticuerpos para detectar transductores de señales múltiples en células de rara circulación
|
BRPI0717416A2
(pt)
|
2006-09-21 |
2013-11-12 |
Prometheus Lab Inc |
Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
|
US20080112961A1
(en)
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
WO2008069881A2
(en)
|
2006-11-06 |
2008-06-12 |
Source Precision Medicine, Inc. |
Gene expression profiling for identification, monitoring and treatment of melanoma
|
AU2007353412A1
(en)
|
2006-11-21 |
2008-11-20 |
Fox Chase Cancer Center |
Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
|
EP2518508A1
(en)
|
2006-11-28 |
2012-10-31 |
U3 Pharma GmbH |
Activated HER3 as a marker for predicting therapeutic efficacy
|
JP2010511382A
(ja)
|
2006-12-01 |
2010-04-15 |
エージェンシー フォー サイエンス,テクノロジー アンド リサーチ |
癌関連タンパク質キナーゼ
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8163886B2
(en)
|
2006-12-21 |
2012-04-24 |
Emd Millipore Corporation |
Purification of proteins
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
JP2010516675A
(ja)
|
2007-01-17 |
2010-05-20 |
イミューノメディクス、インコーポレイテッド |
治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分
|
PL2129396T3
(pl)
|
2007-02-16 |
2014-02-28 |
Merrimack Pharmaceuticals Inc |
Przeciwciała przeciw ERBB3 i ich zastosowania
|
EP2899541A1
(en)
|
2007-03-02 |
2015-07-29 |
Genentech, Inc. |
Predicting response to a HER dimerisation inhbitor based on low HER3 expression
|
PE20090190A1
(es)
|
2007-03-23 |
2009-03-22 |
Smithkline Beecham Corp |
Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
|
EP2132227A1
(en)
|
2007-03-30 |
2009-12-16 |
F. Hoffmann-Roche AG |
Composition of labeled and non-labeled monoclonal antibodies
|
EP2076289B1
(en)
|
2007-04-13 |
2014-11-12 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to erbb therapeutics
|
FR2915115B1
(fr)
|
2007-04-23 |
2010-09-10 |
Sames Technologies |
Organe de pulverisation,dispositif de projection comportant un tel organe,installation de projection et methode de nettoyage d'un tel organe
|
NZ599214A
(en)
|
2007-06-01 |
2013-12-20 |
Univ California |
Multigene prognostic assay for lung cancer
|
CA2687819A1
(en)
|
2007-06-06 |
2008-12-11 |
F.Hoffmann-La Roche Ag |
Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label
|
US20100183504A1
(en)
|
2007-06-14 |
2010-07-22 |
Fanqing Frank Chen |
Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
|
US8501417B2
(en)
|
2007-06-26 |
2013-08-06 |
Vanderbilt University |
Immunological compositions as cancer biomarkers and/or therapeutics
|
US20110038865A1
(en)
|
2007-06-26 |
2011-02-17 |
University Of Miami |
Antibody- endostatin fusion protein and its variants
|
PL2586788T3
(pl)
|
2007-07-09 |
2018-05-30 |
Genentech, Inc. |
Zapobieganie redukcji wiązań disiarczkowych podczas rekombinacyjnego wytwarzania polipeptydów
|
RU2519647C2
(ru)
|
2007-07-13 |
2014-06-20 |
Нестек С.А. |
Выбор лекарственных средств для терапии рака легких с помощью матриц на основе антител
|
WO2009023266A1
(en)
|
2007-08-14 |
2009-02-19 |
Ludwig Institute For Cancer Research |
Generation of antibodies to cell-surface receptors and cancer-associated proteins including egfr family members
|
ES2536772T3
(es)
|
2007-09-21 |
2015-05-28 |
The Regents Of The University Of California |
El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
|
US20110091473A1
(en)
|
2007-10-22 |
2011-04-21 |
Genmab A/S |
Novel antibody therapies
|
US20120047586A9
(en)
|
2007-10-24 |
2012-02-23 |
Otsuka Chemical Co., Ltd |
Polypeptide having enhanced effector function
|
NZ617520A
(en)
|
2008-02-25 |
2015-05-29 |
Nestec Sa |
Drug selection for breast cancer therapy using antibody-based arrays
|
JP2011513432A
(ja)
|
2008-03-06 |
2011-04-28 |
ジェネンテック, インコーポレイテッド |
c−met及びHERアンタゴニストの併用療法
|
EP2106806A1
(en)
|
2008-03-31 |
2009-10-07 |
Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. |
Nanoparticles for targeted delivery of active agents to the lung
|
EP2288715B1
(en)
|
2008-04-11 |
2014-09-24 |
Merrimack Pharmaceuticals, Inc. |
Human serum albumin linkers and conjugates thereof
|
EP2899209A1
(en)
|
2008-04-29 |
2015-07-29 |
Abbvie Inc. |
Dual Variable Domain Immunoglobulins and uses thereof
|
EP2276506A4
(en)
|
2008-04-30 |
2014-05-07 |
Immunogen Inc |
EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
|
WO2009134870A1
(en)
|
2008-04-30 |
2009-11-05 |
Immunogen, Inc. |
Potent cell-binding agent drug conjugates
|
UY31800A
(es)
|
2008-05-05 |
2009-11-10 |
Smithkline Beckman Corp |
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
|
WO2010008726A1
(en)
|
2008-06-16 |
2010-01-21 |
Immunogen Inc. |
Novel synergistic effects
|
EP2138511A1
(en)
|
2008-06-27 |
2009-12-30 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
HER3 as a determinant for the prognosis of melanoma
|
CA2729949A1
(en)
|
2008-07-08 |
2010-01-14 |
Abbott Laboratories |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
AU2009273540A1
(en)
|
2008-07-25 |
2010-01-28 |
Merck Patent Gmbh |
Method of determination of receptor binding saturation effected by monoclonal antibodies
|
US8056451B2
(en)
|
2008-07-28 |
2011-11-15 |
Irwin Industrial Tool Company |
Locking pliers
|
US20100033482A1
(en)
|
2008-08-11 |
2010-02-11 |
Interactive Relighting of Dynamic Refractive Objects |
Interactive Relighting of Dynamic Refractive Objects
|
EA022884B1
(ru)
|
2008-08-15 |
2016-03-31 |
Мерримак Фармасьютикалз, Инк. |
СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА
|
EP2340305A1
(en)
|
2008-09-26 |
2011-07-06 |
Eureka Therapeutics, Inc. |
Cell lines and proteins with variant glycosylation pattern
|
CN102271712B
(zh)
|
2008-10-31 |
2015-11-25 |
通用医疗公司 |
用于将物质递送至生物靶标的组合物和方法
|
JP2012507299A
(ja)
|
2008-10-31 |
2012-03-29 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Light標的分子およびその使用
|
JP5677972B2
(ja)
|
2008-11-18 |
2015-02-25 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ヒト血清アルブミンリンカーおよびそのコンジュゲート
|
US20100169729A1
(en)
|
2008-12-30 |
2010-07-01 |
Datta Shamanna M |
Enabling an integrated memory controller to transparently work with defective memory devices
|
EP2380025B1
(en)
|
2009-01-14 |
2013-09-11 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Ratio based biomarkers and methods of use thereof
|
EP2387717B1
(en)
|
2009-01-15 |
2014-12-10 |
Laboratory Corporation of America Holdings |
Methods of determining patient response by measurement of her-2 expression
|
BRPI1007321A2
(pt)
|
2009-01-15 |
2018-07-10 |
Laboratory Corp America Holdings |
métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
|
DK3912643T3
(da)
|
2009-02-13 |
2022-10-17 |
Immunomedics Inc |
Immunokonjugater med en intracellulært-spaltelig binding
|
CA2753119A1
(en)
|
2009-02-24 |
2010-09-02 |
F. Hoffmann-La Roche Ag |
Use of s-erbb-3 as a marker for cancer
|
WO2010099186A1
(en)
|
2009-02-25 |
2010-09-02 |
Merck Sharp & Dohme Corp. |
Her2 antibody compositions
|
CA2755640C
(en)
|
2009-03-20 |
2018-05-22 |
Genentech, Inc. |
Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
|
US8362215B2
(en)
|
2009-04-29 |
2013-01-29 |
Trellis Bioscience, Llc |
Antibodies immunoreactive with heregulin-coupled HER3
|
EP2435071A1
(en)
|
2009-05-29 |
2012-04-04 |
F. Hoffmann-La Roche AG |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
CA2766405A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
Engineered fc regions for site-specific conjugation
|
RU2573894C2
(ru)
|
2009-08-06 |
2016-01-27 |
Дженентек, Инк. |
Способ усовершенствования процесса удаления вирусов при очистке белков
|
US20110039300A1
(en)
|
2009-08-10 |
2011-02-17 |
Robert Bayer |
Antibodies with enhanced adcc functions
|
AU2010284018C1
(en)
|
2009-08-21 |
2015-10-15 |
Merrimack Pharmaceuticals, Inc. |
Antibodies against the ectodomain of ErbB3 and uses thereof
|
WO2011031840A1
(en)
|
2009-09-09 |
2011-03-17 |
Quintiles Transnational Corp. |
Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
|
LT2486141T
(lt)
|
2009-10-07 |
2018-05-25 |
Macrogenics, Inc. |
Fc regioną turintys polipeptidai, pasižymintys pagerinta efektorine funkcija dėl fukozilinimo laipsnio pasikeitimų, ir jų naudojimo būdai
|
AU2010303443A1
(en)
|
2009-10-09 |
2012-04-19 |
Merck Sharp & Dohme Corp. |
Generation, characterization and uses thereof of anti-Her 3 antibodies
|
EP2488199A1
(en)
|
2009-10-14 |
2012-08-22 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
|
DK3351558T3
(da)
|
2009-11-13 |
2020-06-02 |
Daiichi Sankyo Europe Gmbh |
Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
|
CA2784211C
(en)
|
2010-02-18 |
2019-12-24 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
EP2542699A4
(en)
|
2010-03-03 |
2013-10-02 |
Targeted Molecular Diagnostics Llc |
METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
|
PT2544680E
(pt)
|
2010-03-11 |
2015-05-06 |
Merrimack Pharmaceuticals Inc |
Uso de inibidores de erbb3 no tratamento de cancro da mama triplo negativo
|
WO2011136911A2
(en)
|
2010-04-09 |
2011-11-03 |
Aveo Pharmaceuticals, Inc. |
Anti-erbb3 antibodies
|
WO2011139629A2
(en)
|
2010-04-26 |
2011-11-10 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
WO2011143414A1
(en)
|
2010-05-13 |
2011-11-17 |
Fox Chase Cancer Center |
RECOMBINANTLY PRODUCED ANTIBODIES TARGETING ErbB SIGNALING MOLECULES AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF DISEASE
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
SG185354A1
(en)
|
2010-05-20 |
2012-12-28 |
Ablynx Nv |
Biological materials related to her3
|
AU2012211258A1
(en)
|
2011-01-27 |
2013-03-21 |
Merrimack Pharmaceuticals, Inc. |
Treatment of advanced solid stage tumors using anti-ErbB3 antibodies
|
BR112013019499B1
(pt)
|
2011-02-04 |
2023-01-10 |
Genentech, Inc. |
Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
|
WO2012106578A1
(en)
|
2011-02-04 |
2012-08-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
|
JP6228014B2
(ja)
|
2011-02-07 |
2017-11-08 |
リサーチ ディベロップメント ファウンデーション |
操作された免疫グロブリンFcポリペプチド
|
ES2687771T3
(es)
|
2011-03-06 |
2018-10-29 |
Merck Serono Sa |
Líneas de células con bajo nivel de fucosa y sus usos
|
CA3212002A1
(en)
|
2011-03-17 |
2012-09-20 |
Cernostics, Inc. |
Systems and compositions for diagnosing barrett's esophagus and methods of using the same
|